Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study.

ABSTRACT: Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and consolidation chemotherapy alone or in combination with different therapeutic approaches remain the main treatment. Although complete or partial remission of the disease can be achieved, the risk of relapse or refractory leukemia is still high. More effective and safe therapy options are yet unmet needs. In recent years' new therapeutic approaches have been widely used. Hematopoietic Stem Cell Transplantation (HSCT) presents significant limitations and the outcome of the consolidation treatment is patient dependent. Side effects such as Graft versus Host Disease (GvHD) in allogeneic hematopoietic stem cell transplantation are extremely common, therefore, using alternative methods to address these challenge

SUBMITTER: Sheykhhasan M 

PROVIDER: S-EPMC9395272 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature